Of all age groups, the newborn are the most susceptible to septicemia. It is also the age group -when the verification of the diagnosis of septicxmia is the most difficult. Starting antibacterial treatment as early as possible is, however, of decisive importance for the outcome. The administration of antibiotics on mere suspicion of septicaemia is thus unavoidable.
An antibiotic to be used as the primary drug when suspecting septictemia in the newborn should fulfil following criteria:
(1) Its mode of action should be bactericidal since the defence of the newborn is still weak.
(2) It should be non-toxic, since so many childrep receive it on mere suspicion of septicaemia. The unpredictability and the fast change in the function of both kidneys and liver of the newborn make proper dosage difficult and increase the importance of lack of toxicity.
(3) It should penetrate well into tissues. The achievement of concentration in the CSF, even through non-inflamed meninges is important, for it is probable that in the newborn period bacteria may reach the meninges from the pharynx, without entering the blood stream. (4) It should not be tightly bound to serum proteins since such a drug might interfere with the binding of bilirubin. (5) It should of course be effective against those bacteria most commonly affecting the newborn.
When looking for an antibiotic to be used as the primary drug for the suspicion septicemia in the newborn, cefuroxime seemed to fulfil these criteria rather well. It is a bactericidal drug which is said to be non-toxic. In vitro it is active against the bacteria most commonly encountered in newborn septicemias, and its rate of protein binding is relatively low.
There were, however, very few data available on the use of cefuroxime in the newborn period. We therefore decided to start a pilot study in order to establish the main pharmacokinetic facts about cefuroxime in this age group.
Patients and Methods
These studies were performed on 104 children under the age of 3 weeks, treated at the Children's Hospital, University of Helsinki, using cefuroxime for suspected or established infections, between February 15th and September 15th 1977. Estima-tions of cefuroxime were performed with the standard bioassay method.
RESULTS

Peak Concentrations
Serum concentrations 30-60 min after i.m. injection of 10 mg/kg were determined in 96 children.
As expected, the bigger and more mature the child, the lower the concentration. The difference is, however, rather small. The peak values are in general between 15 and 25 jug/ml (Table 1) .
Half-Life
In 10 children, serum cefuroxime concentrations were assayed for 6-8 h after the first i.m. injection of 10 mg/kg.
There is a rather wide distribution, as the age of the children also varied. When calculated by semi-logarithmic linear regression analysis for each child separately, the half-life of cefuroxime varied from 214-338 min (mean 275 ±44) being clearly related to the age of the child (Table 2) . It is thus 3-5 times longer than in adults. There was no correlation between the half-life and the gestational ages of the children.
Accumulation ofthe Drug
The serum concentrations of cefuroxime were assayed 30-60 min after injection in 53 patients receiving 10 mg/kg three times daily for at least 5 days. Measurements were made on every day or every second day, at least 3 times during the treatment. The results (Fig 1, Table 3 ) show that no accumulation occurred. Serum concentrations 30-60 min before and after the injection of cefuroxime were assayed in 5 patients, 2 weighing 2000 g and 3 weighing <4000 g, and there is seen to be a somewhat higher value in the smaller children (Table 4 ). 69.6', Urinary Excretion
Twenty-four hour urine was collected from 36 patients, usually between the second and fifth days of treatment. There were great vat iations in the concentration of cefuroxime in urine and in the proportion of the daily dose excreted, due in part to difficulties in urine collection. The urinary concentrations of cefuroxime were generally about 10 times higher than in the serum values (Table 5 ). When correlating urinary concentrations with age (Fig 2) there was a marked diminution with increasing age, probably due to increased amounts of urine.
Cerebrospinal Fluid Measutrements
The CSF concentrations of cefuroxime were obtained from 9 patients. Three of them had (Table 6 ) and the concentration of cefuroxime in their CSF varied from 2.3-5.3 jug/ ml, thus being 12-25% of the serum concentration. In another 3 patients without signs of meningitis, the values varied from 0.4-1.5 ,ug/ml.
In 2 patients, himorrhages into the CSF had occurred and the values were 1.4-3.0 jug/ml. One patient, 1 month old, with post surgical meningomyeloccele and ventriculostoma, was given cefuroxime 10 mg three times daily. The peak serum concentrations rose to 20 ,ug/ml. The intraventricular fluid concentrations were followed for 18 h at 1-2 h intervals. They remained from 2.9-5.0 ,ug/ml. The protein content of the fluid was very high.
Side Effects
The following serum parameters were monitored in some or all of the patients to try to detect any side effects: hemoglobin, platelets, WBC, Saspartate amino transferase (ASAT), blood urea nitrogen (BUN) and bilirubin. Due to difficulties in sampling, this schedule could not be strictly enforced. Thus S-ASAT was followed in 22 patients and BUN in 44, while bilirubin and hxmatologic data were followed in all 76. The only abnormalities in these laboratory tests which could be attributed to the drug were 4 cases of elevated BUN. The treatment was continued and in all of the cases the BUN values became normal when the infections had subsided. Another 4 patients developed a rash. In these also the treatment was continued and the rash disappeared after 1-2 days. One patient developed a diarrhcea at the end of 20 days of cefuroxime treatment.
Side effects were thus almost non-existent.
Clinical Evaluation
Of the 76 patients treated with cefuroxime for 5 days or more, only 8 had well defined bacteriology. Three were cases of septicemia caused by Escherichia coli, Streptococcus type B and Staphylococcus epidermidis. Three were severe skin infections that did not respond to local treatment, and were caused by Staphylococcus aureus. One was a urinary infection caused by Escherichia coli, and found by bladder puncture. All of these cases recovered.
One patient was considered a failure on cefuroxime. This patient developed a bacterial meningitis during treatment with cefuroxime which was caused by a sensitive Staphylococcus aureus. When the drug was changed, the child recovered. Sixty-eight more patients received cefuroxime as the sole drug when treated for suspected septicaemia and/or respiratory infections where no certain bacteriological findings could be made. All of these patients recovered, but might have done so without antibiotics.
Summary
Cefuroxime has been administered for suspected or verified bacterial infections to 104 children aged less than 3 weeks. Some basic data concerning the pharmacokinetics of cefuroxime in this age grotup have been evaluated.
The serum concentrations 30-60 min after i.m. injection of 10 mg/kg of cefuroxime usually vary from 15-25 ,ug/ml. The half-life of the drug in newborns varies from 3.5-5.5 h, depending on the age of the child. It is thus 3-5 times longer than in adults.
Using a dosage of 10 mg/kg three times daily no accumulation was observed in full-term infants. For those with a birth weight <c2000 g higher peak values and some accumulation were observed especially during the first days of life. Thus a twice daily dosage during the first days of life seems appropriate in this group of patients. The urinary concentrations varied in most instances from 150-400 jug/ml, being about 10 times higher than in serum. Concentrations in the CSF were measured in 8 patients. In 3 suffering from meningitis the values were 15-25% of the serum concentrations. fn 3 children with no signs of meningitis, measurable amounts of cefuroxime were found, varying from 0.4-1.5 ug/ml. Side effects were almost non-existent. In 4 patients a rash appeared, but subsided in 1-2 days when the treatment was continued. Long term side effects are still unknown. Clinical experience with well defined bacteriology was limited to 8 cases. Seven recovered and 1 was a failure. Of the patients who recovered, 3 had septicaemia, I urinary infection and 3 skin infections. The failure was a patient developing meningitis during the treatment. Sixty-eight other patients who received cefuroxime for 5 days or more recovered, but no bacteriological diagnosis could be established. So far the drug seems promising in the treatment of suspected infections in the newborn.
